Jillian Dabney
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Jillian Dabney
Company & Industry OverviewsThe Competitive Landscape for Enbrel
Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015.
Company & Industry OverviewsWhen Will the Biosimilar for Enbrel Be Available?
In the absence of biosimilars, the biotechnology industry enjoys benefits after patent expiry for a longer period.
Company & Industry OverviewsEnbrel Sales Were Flat in 3Q16
Amgen (AMGN) is primarily focused on six therapeutic areas: oncology/hematology, cardiovascular, inflammation, bone health, neuroscience, and nephrology.
Company & Industry OverviewsWhy Is Enbrel So Important for Amgen?
YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.
Company & Industry OverviewsWhat’s Behind Amgen’s Discounted Valuation?
Amgen’s top-line growth is under pressure following the rising competition for key drug Enbrel, which had a 26% share in Amgen’s total product sales in 3Q16.
Company & Industry OverviewsWhat Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
Company & Industry OverviewsRevenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
Company & Industry OverviewsGauging the Performance of Horizon Pharma’s Rayos in 3Q16
During the third quarter of 2016, Rayos, a delayed-release prednisone, rose 15.0% to $13.4 million compared to 3Q15.
Company & Industry OverviewsFactors behind Horizon Pharma’s Volatility in December
With the Express Scripts agreement, Horizon Pharma’s net sales in 2017 are expected to rise. The probability of a top-line expansion has boosted investor sentiment.
Company & Industry OverviewsHow Did Horizon Pharma Perform in 3Q16?
In 3Q16, Horizon Pharma’s (HZNP) net sales on a GAAP basis fell to $208.7 million. Non-GAAP net sales were $273.7 million.
Company & Industry OverviewsHorizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
Company & Industry OverviewsWhat Were Pfizer’s Major Achievements in 2016?
During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.
Company & Industry OverviewsPfizer Has Strong Track Record since 2010
As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.
Company & Industry OverviewsHow Much Could Pfizer Grow beyond 2016?
Year-to-date, Pfizer’s (PFE) stock has already fallen 4.2%. Despite its multiple acquisitions to boost its falling top line, investors are cautious about the company.
Company & Industry OverviewsLoss of Patent Protection to Drag Pfizer’s Top Line
With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.
Company & Industry OverviewsLyrica to Lose Patent Protection in the US in 2018
After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.
Company & Industry OverviewsExploring Avelumab’s Opportunities in the PD-1/PD-L1 Space
Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.
Company & Industry OverviewsAvelumab: The First US Treatment for Metastatic Skin Cancer?
Pfizer’s avelumab seems to be its potential growth driver for the next one to five years. Pfizer is developing the product with its partner Merck KGaA.
Company & Industry OverviewsIbrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.
Company & Industry OverviewsUnderstanding Pfizer’s 3Q16 Performance
During 3Q16, Pfizer (PFE) recorded revenue amounting to $13 billion. Excluding the impact of foreign exchange, the company’s revenue rose 8% annually.
Company & Industry OverviewsListing the Reasons behind Pfizer’s Discounted Price-to-Earnings
Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.
Earnings ReportInside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
Earnings ReportHow Did Mallinckrodt’s Specialty Brands Perform in 2016?
Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.
Earnings ReportMallinckrodt’s Revenue Growth in Fiscal 4Q16
On an annual basis, MNK’s net sales soared by 16% to $3.4 billion in 2016. Despite its better-than-estimated performance, shares fell by 9% on November 29.
Company & Industry OverviewsYes, There Will Be Margin Erosion for Valeant in 2017
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Company & Industry OverviewsWhat Does Valeant’s Institutional Ownership Look Like?
Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.
Company & Industry OverviewsMallinckrodt’s Greater Dependence on Acthar and Generic Business
Mallinckrodt (MNK) has recently been making news due to its business model being questioned. A Citron Research report focused on the sustainability of Acthar’s higher level of exposure to government-oriented franchise.
Company & Industry OverviewsHow Could Gilead Sciences Restore Its Growth?
With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.
Company & Industry OverviewsWhat Do Analysts Recommend for Gilead Sciences Stock?
According to a Reuters consensus of 26 brokerage firms on November 22, 2016, 88% of the analysts recommended Gilead as a “buy.”
Company & Industry OverviewsHow Much Could Gilead Sciences’s Revenues Fall beyond 2016?
Gilead Sciences (GILD) is expected to garner $28.3 billion in 2017 and $26.7 billion in 2018.
Company & Industry OverviewsEpclusa: Gilead Sciences’s Pan-Genotype Product
With its costly HCV drugs, Gilead Sciences (GILD) has one of the highest net margins in the biotechnology industry.
Company & Industry OverviewsCould There Be a Steep Fall for Gilead Sciences’s HCV Franchise?
With three products—Sovaldi, Harvoni, and Epclusa—in its arsenal, Gilead Sciences (GILD) dominates the HCV (hepatitis C virus) market.
Company & Industry OverviewsHow Could TAF-Based Regimen Drive Gilead Sciences’s Growth?
Gilead Sciences’s (GILD) TAF-based (tenofovir alafenamide) regimen comprises three products: Genvoya, Descovy, and Odefsey.
Company & Industry OverviewsGilead Sciences’s HCV Fall Was Partially Offset by HIV Business
During 3Q16, Gilead Sciences’s (GILD) total revenues fell 10% to $7.5 billion.
Company & Industry OverviewsGilead Sciences Holds a Broader HIV Portfolio
Gilead Sciences (GILD) holds a share of nearly 80% in the antiretroviral therapy market, which covers ~840,000 patients.
Company & Industry OverviewsIs Gilead Sciences Stock Oversold?
When compared with its estimated $30.2 billion total revenue for 2016, Gilead Sciences’s (GILD) $99 billion market capitalization on November 23 seemed to be at a greater discount. GILD had a forward PE ratio of ~7.0x against its peers’ average PE of ~12.1x.
Company & Industry OverviewsBMY’s Orencia Has Been Approved to Treat Methotrexate-Naive Patients
BMY’s Orencia is the only biologic approved for three modes of administration (IV infusion, prefilled syringes, and autoinjectors) for treating RA.
Company & Industry OverviewsInside Bristol’s Key to Success: Multiple Labels for Opdivo
Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.
Company & Industry OverviewsBristol’s Opdivo Has One Eye on Advanced Bladder Cancer
After its 3Q16 earnings, there were multiple positive triggers for Bristol-Myers Squibb (BMY) stock.
Company & Industry OverviewsWhy Is Lung Cancer so Attractive to Bristol, Merck, and Roche?
Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.
Company & Industry OverviewsBrace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.
Company & Industry OverviewsYes, It’s a Similar Label for Opdivo and Tecentriq in Lung Cancer
Despite fierce competition in the lung cancer space, Opdivo is leading with its superior safety and efficacy profile.
Company & Industry OverviewsOpdivo’s Approval for Head and Neck Cancer: Another Feather in Bristol’s Cap?
During the third quarter of 2016, Bristol-Myers Squibb (BMY) fetched revenues of $4.9 billion—a 21% rise.
Macroeconomic AnalysisHow Could Trump’s Presidency Affect Hospitals and Insurance?
The effects of repealing Obamacare Donald Trump is definitely not in favor of the Affordable Care Act, known as Obamacare. As he wants to repeal the act completely and replace it with another policy, the hospital sector fell on November 9, the day after the election. Trump believes that providing healthcare facilities to illegal immigrants costs […]
Macroeconomic AnalysisWhat Is Donald Trump’s Seven-Point Health Plan?
Trump’s healthcare agenda During his campaign, Trump came up with a seven-point plan for the healthcare industry. In this plan, he proposed to repeal the Affordable Care Act. Although a complete repeal doesn’t seem feasible, if applied, it would definitely take a toll on hospitals and insurance companies. In the next article, we’ll discuss the severity of […]
Earnings ReportNeurology, Generics Businesses Drag Valeant’s 2017 Revenue and EBITDA
During 3Q16, Nitropress earned $36 million compared with $35 million in 3Q15.
Earnings ReportHow Did the Bausch & Lomb Division Perform in 3Q16?
Over the past five quarters, the Bausch & Lomb business had shown a variation in the margins, where its gross margin fell to 61% in 3Q16 from 67% in 3Q15.
Earnings ReportGreat Disappointment in Valeant Pharmaceuticals’s 3Q16 Earnings
Valeant Pharmaceuticals (VRX) announced its 3Q16 earnings on November 8. On a GAAP basis, Valeant reported a loss of ~$1.2 billion, which reflects a loss of $3.49 per diluted share during the period.
Earnings ReportWhat Do Analysts Say about Regeneron after 3Q16 Earnings?
Regeneron Pharmaceuticals (REGN) released earnings for 3Q16 on November 4, 2016.
Earnings ReportWhat Drove Regeneron’s 3Q16 Performance?
In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.
Company & Industry OverviewsWhy Valeant Has Been in the News Recently
On November 3, 2016, Valeant along with many other generic and Specialty Pharma drug companies plunged.
Company & Industry OverviewsWhat Do Analysts Recommend for Valeant after Recent Happenings
The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.
Company & Industry OverviewsHow Could a Salix Sale Impact Valeant’s Financials?
With the sale of Salix, Valeant’s adjusted revenues will fall 14.0%. Since Salix is a high-margin business, the sale will adversely impact Valeant’s margins.
Company & Industry OverviewsWhat Might Have Fueled Valeant’s Interest in Salix?
The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.
Company & Industry OverviewsValeant’s Salix Acquisition Saga
Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.
Earnings ReportWhat Do Analysts Recommend for Novo?
Danish company Novo Nordisk (NVO) released earnings for 3Q16 on October 28, 2016.
Earnings ReportHow Did Novo’s Biopharmaceuticals Segment Perform in 3Q16?
Novo’s (NVO) Biopharmaceuticals segment rose 5.2 billion Danish kroner during 3Q16.
Earnings ReportHow Tresiba Helps Novo Achieve Its Growth Targets
During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.
Earnings ReportReading Novo’s Insulin Portfolio to Find Clues about Its Growth
Novo Nordisk’s (NVO) diabetes and obesity care portfolio consists of modern insulin, Victoza, human insulin, new generation insulin, and other diabetes and obesity care products.
Earnings ReportVictoza Dominates Global GLP-1 Class
Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.
Earnings ReportNovo’s Dominance in Global Diabetes Market
In the diabetes space, Novo shares the market with Sanofi (SNY), Eli Lilly (LLY), and Merck (MRK).
Earnings ReportUS Still the Largest Market for Novo Nordisk
During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.
Earnings ReportAnalyzing Novo’s Revenue Growth in 3Q16
During 3Q16, Novo Nordisk’s (NVO) net sales rose 2.8% to 27.5 billion Danish kroner from 26.8 billion Danish kroner in 3Q15.
Earnings ReportHoning in on Novo’s 3Q16 Revenue and Earnings
Novo Nordisk (NVO) disappointed investors with reported revenues of ~27.5 billion Danish kroner for 3Q16.
Earnings ReportBioMarin’s Disappointing 3Q16 Earnings
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.
Earnings ReportHow Much Is the Return Opportunity for Novo Nordisk in 3Q16?
A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.
Earnings ReportRoche’s Disappointing 3Q16 Earnings
Roche Holding (RHHBY) reported earnings for 3Q16 on October 20, 2016. Wall Street analysts expected Roche to report 12.6 billion Swiss francs in revenue during 3Q16 while the company reported ~12.5 billion Swiss francs.
Earnings ReportStrensiq and Kanuma: Potential Revenue Drivers for Alexion
Once Alexion taps the numbers of Strensiq and Kanuma, its share price will most likely rise.
Earnings ReportWhat Are the Drivers behind the Success of Soliris?
Following analysts’ projections, Soliris revenues in 3Q16 and 4Q16 should rise 9.0% and 10.0%, respectively, YoY to reach $725.9 million and $760.6 million, respectively.
Earnings ReportWhy Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
Earnings ReportWhy Vertex Lowered Its Guidance for Orkambi
The slower launch of Orkambi in Germany is to blame for the drug’s lowered guidance.
Earnings ReportVertex Not the Only Pharmaceutical to See Its Share Price Fall
Over the past year, VRTX stock has fallen 31.0%. But perhaps the entire biotechnology industry, not just Vertex, has suffered during the period.
Company & Industry OverviewsPfizer’s Divestment of Hospira Infusion Systems
On October 6, 2016, Pfizer (PFE) announced one deal to “off-load” all of the global infusion therapy business known as “Hospira Infusion Systems.”
Company & Industry OverviewsFour Key Deals: Analyzing Pfizer’s Impending Growth
Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.
Company & Industry OverviewsDid Pfizer’s Top Line Growth Beat Its Peers?
Over the past two years, Pfizer hasn’t really offered lucrative returns to shareholders. The stock rose 13% from October 10, 2014, to October 11, 2016.
Company & Industry OverviewsDoes Pfizer Deserve a Better Valuation?
Like other big pharmaceutical companies, Pfizer witnessed negative top line growth. With multiple acquisitions recently, it’s poised to grow its top line.
Company & Industry OverviewsHow Large of a Role Does Opdivo Play in Bristol-Myers Squibb’s Success?
In the US, the Opdivo and Yervoy combination is the most prescribed regimen in first-line metastatic melanoma.
Company & Industry OverviewsBristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market
With Bristol-Myers Squibb’s (BMY) Opdivo being the standard of care in the second-line lung cancer space, it faces cutthroat competition from Merck’s (MRK) Keytruda.
Company & Industry OverviewsWhat Do Analysts Have to Say about Bristol-Myers Squibb?
Analyst recommendations for BMY Bristol-Myers Squibb (BMY) is a leading immuno-oncology company. According to a Bloomberg consensus of 26 brokerage firms recorded on October 5, 2016, 42.3% of analysts recommended Bristol as a “buy” and 50% of analysts issued a “hold” rating for the company. Around 7.7% of analysts rated the stock as a “sell.” The […]
Company & Industry OverviewsKeytruda Leads over Opdivo in Head and Neck Cancer Treatment
CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]
Company & Industry OverviewsBristol-Myers Squibb’s Premium Valuation
Bristol-Myers Squibb’s valuation On October 5, 2016, Bristol-Myers Squibb (BMY) was trading at 12.98x its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple. The valuation multiple was quite close to that of Eli Lilly and Company (LLY), which was trading at 13.04x its forward EBITDA. Peers Celgene (CELG), Roche (RHHBY), […]
Company & Industry OverviewsUnderstanding the Recent Fall in Bristol-Myers Squibb’s Valuation
On October 4, 2016, Bristol-Myers Squibb (BMY) was trading at a forward PE (price-to-earnings) multiple of 16.8x. With products Opdivo and Yervoy, the company leads the immuno-oncology space.
Company & Industry OverviewsAllergan Enters the Attractive NASH Market
Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.
Company & Industry OverviewsUnderstanding Gilead Sciences’ NASH Pipeline
Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.
Company & Industry OverviewsDescovy and Odefsey: Gilead Sciences’ Recently Approved TAF-Based Products
Gilead Sciences (GILD) recently launched three TAF-based (tenofovir alafenamide) STRs (single-tablet regimens), including Genvoya, Descovy, and Odefsey.
Company & Industry OverviewsBehind Gilead Sciences’ Dominance in HIV
Gilead’ share in the HIV space in terms of overall volume translates to ~78%, whereas 627,000 patients have remained on Gilead’s regimen.
Company & Industry OverviewsRegeneron Is a Late Entrant in Immuno-Oncology Space
Immuno-oncology has been quite an interesting area with increasing innovation and lot of new developments.
Company & Industry OverviewsWhy Teva and Regeneron Entered Collaboration Agreement
On September 20, 2016, Regeneron Pharmaceuticals (REGN) entered a collaboration agreement with Teva Pharmaceuticals (TEVA).
Company & Industry OverviewsHow Regeneron Is Working to Maintain Eylea’s Dominance
Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.
Company & Industry OverviewsA Look at BioMarin’s Early Stage Pipeline
BioMarin’s (BMRN) early-stage pipeline includes BMN-270, a gene therapy program for hemophilia A and vosoritide, which is indicated for achondroplasia.
Company & Industry OverviewsBioMarin to Cross $1 Billion Revenue in 2016
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
Company & Industry OverviewsHow Promising is BioMarin’s Late-Stage Pipeline?
BioMarin’s application for cerliponase alfa, an enzyme replacement therapy, is under review by the FDA for the treatment of CLN2 disease.
Company & Industry OverviewsWhat’s the Word on Street for Vertex?
The Bloomberg consensus of 24 brokerage firms shows that 66.7% brokerage firms recommend Vertex as a “buy,” while 33.3% analyst issued a “hold” ratings.
Company & Industry OverviewsCystic Fibrosis Treatment Is a Space Where Vertex Could Thrive
The addressable population for Vertex Pharmaceuticals’ (VRTX) two commercialized products Kalydeco and Orkambi is currently 27,000.
Company & Industry OverviewsHigher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.
Company & Industry OverviewsGilead’s TAF-Based Regimen Should Drive HIV Franchise Revenue
With products such as Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla and Truvada, Gilead Sciences (GILD) dominates the HIV market.
Company & Industry OverviewsHow Gilead Dominates the HCV Space
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
Company & Industry OverviewsPopulation Dynamics for Gilead’s HCV Products
There are six distinct genotypes of HCV (hepatitis C virus). If we know the genotype, recommending the treatment and duration becomes easier.
Company & Industry OverviewsThe Factors behind Gilead’s Discounted Valuation
On September 20, 2016, Gilead Sciences (GILD) was trading at a forward PE (price-to-earnings) multiple of 7.14x, which was at a discount compared to its peers.
Company & Industry OverviewsProcysbi: Major Addition to Horizon’s Orphan Drug Portfolio
According to Horizon Pharma’s (HZNP) estimates, Procysbi holds a peak sales potential of more than $300 million.